MX9803801A - Type ix collagen and chimeras. - Google Patents

Type ix collagen and chimeras.

Info

Publication number
MX9803801A
MX9803801A MX9803801A MX9803801A MX9803801A MX 9803801 A MX9803801 A MX 9803801A MX 9803801 A MX9803801 A MX 9803801A MX 9803801 A MX9803801 A MX 9803801A MX 9803801 A MX9803801 A MX 9803801A
Authority
MX
Mexico
Prior art keywords
type
collagen
collagens
chimeras
novel
Prior art date
Application number
MX9803801A
Other languages
Spanish (es)
Other versions
MXPA98003801A (en
Inventor
Eero Vuorio
George Martin
Thomas B Neff
Leena Ala-Kokko
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX9803801A publication Critical patent/MX9803801A/en
Publication of MXPA98003801A publication Critical patent/MXPA98003801A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel collagens, polynucleotide sequences encoding these novel proteins, and to the use of these novel proteins and polynucleotides in the diagnosis and treatment of disease. The present invention further relates to specific collagens and derivatives, specifically fusion proteins of type IX collagen with type II and/or type XI collagens, and their use as therapeutic agents.
MXPA/A/1998/003801A 1995-11-13 1998-05-13 Collapse of type ix and quime MXPA98003801A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US660895P 1995-11-13 1995-11-13
US006608 1995-11-13
US74553996A 1996-11-12 1996-11-12
US745539 1996-11-12

Publications (2)

Publication Number Publication Date
MX9803801A true MX9803801A (en) 1998-10-31
MXPA98003801A MXPA98003801A (en) 1999-01-11

Family

ID=

Also Published As

Publication number Publication date
EP0861086A1 (en) 1998-09-02
JP2001510981A (en) 2001-08-07
IL124437A0 (en) 1998-12-06
NO982181L (en) 1998-07-06
BR9611547A (en) 1999-06-15
CA2237900A1 (en) 1997-05-22
NO982181D0 (en) 1998-05-13
WO1997017988A1 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
WO1996034953A3 (en) Cd16-ii variants
DE69942365D1 (en) TARGETED SUPPLY OF PHARMACEUTICAL AGENTS TO INJURED TISSUE
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
CA2257133A1 (en) Human dnase i hyperactive variants
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
EP0849361A3 (en) Novel ligands of the neuropeptide receptor HFGAN72
EP0815202A4 (en) Human tissue inhibitor of metalloproteinase-4
DE69534180D1 (en) PROMOTER OF TIE RECEPTOR PROTEIN KINASE
NO982181L (en) Type IX collagen and chimeras
EP0330396A3 (en) Dna sequences, recombinant dna molecules and processes for producing lipocortins iii, iv, v & vi
ITBO930059A0 (en) PROCEDURE TO OBTAIN TISSUE REGENERATION IN PERIODENTAL DENTISTRY THERAPY.
HUP0003116A2 (en) Betha-amyloid peptide-binding proteins and polynucleotides encoding the same
KR100488038B1 (en) New bpc peptide salts with organo-protective activity the process for their preparation and their use in therapy
EP0870036A4 (en) Synthetic mammalian alpha-n-acetylglucosaminidase and genetic sequences encoding same
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
ATE343633T1 (en) ALLEL FORMS OF HUMAN STATUS3
BG105682A (en) Bone stimulating factor
DE69730967D1 (en) Human dnase ii
WO2002026980A3 (en) Human ion-exchanger proteins and polynucleotides encoding t he same
WO2002010380A1 (en) A novel polypeptide, a kruppel-like zinc finger protein zk110.12 and the polynucleotide encoding the polypeptide
WO2002098913A3 (en) Polypeptides and corresponding polynucleotides for prophylaxis and treatment of colon cancer
WO2001075010A3 (en) A novel polypeptide, human nuclear transduction protein 25 containing a structural atp/gtp domain
CA2200846A1 (en) Promoter for the receptor tyrosine kinase, tie
ATE94759T1 (en) USE OF DEXTRANSULFATE, OPTIONALLY IN COMBINATION WITH ANTI-ANDROGENIC AGENTS FOR THE TREATMENT OF HUMAN PROTATE CANCER.